ProKidney Corp. is a biotechnology company developing rilparencel, an autologous cell therapy that uses a patient's own kidney cells to preserve kidney function in patients with advanced chronic kidney disease and type 2 diabetes. The therapy involves extracting cells from a patient's kidney tissue, expanding them in the company's manufacturing facility, and reinjecting them into the patient's damaged kidneys through a minimally invasive outpatient procedure; because the product uses the patient's own cells, immunosuppressive therapy is not required. The company generates value through the development and eventual commercialization of rilparencel, targeting a large patient population across multiple disease stages, with revenue dependent on regulatory approval and market adoption of the therapy once it becomes available.